Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941109 | 1.00 | CYP2C19 (0.53) | CYP2C19METPKML3MBTL1KMT2A | |
| SCHEMBL1780348 | 0.88 | L3MBTL1 (0.55) | CYP2C19METPKML3MBTL1KMT2A | |
| SCHEMBL28695590 | 0.82 | HTR6 (0.51) | CYP2C19METPKML3MBTL1KMT2A | |
| SCHEMBL25190824 | 0.81 | CYP2C19 (0.44) | CYP2C19METPKMKMT2AMEN1 | |
| SCHEMBL29428770 | 0.81 | CYP2C19 (0.44) | CYP2C19METPKMKMT2AMEN1 | |
| SCHEMBL28735217 | 0.81 | HTR6 (0.46) | CYP2C19METPKMKMT2AMEN1 | |
| SCHEMBL29428833 | 0.81 | CYP2C19 (0.44) | CYP2C19METPKMKMT2AMEN1 | |
| SCHEMBL17628727 | 0.81 | CYP2C19 (0.44) | CYP2C19METKMT2AMEN1RAB9A | |
| SCHEMBL2273205 | 0.81 | CYP2C19 (0.44) | CYP2C19METPKMKMT2AMEN1 | |
| SCHEMBL1669689 | 0.81 | CYP2C19 (0.44) | CYP2C19METL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161324-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-115215861-B | Aromatic heterocycle substituted alkyne compound and preparation method and application thereof | 上海翊石医药科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-115215861-A | Aromatic heterocycle substituted alkyne compound and preparation method and application thereof | 上海翊石医药科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10640485-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190119249-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| EP-3416638-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| US-10138219-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS (US) | 2018-11-27 | — | — | US | disclosed |
| WO-2017143291-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017143291-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CYP2C19 4845/4885MET 319/4885PKM 3600/4885 |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CYP2C19 4845/4885MET 319/4885PKM 3600/4885 |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CYP2C19 4845/4885MET 319/4885PKM 3600/4885 |
| US-20190119249-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CYP2C19 4845/4885MET 319/4885PKM 3600/4885 |
| US-10640485-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CYP2C19 4845/4885MET 319/4885PKM 3600/4885 |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CYP2C19 4845/4885MET 319/4885PKM 3600/4885 |
| US-10138219-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CYP2C19 4845/4885MET 319/4885PKM 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.